Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

HMPL-A83

Monoclonal antibody · Antagonist of CD47 · developed by Hutchmed

Phase 1 Most advanced trial (none active)
HCM Developer
1 Registered trials

What is HMPL-A83?

HMPL-A83 is a humanized IgG4 monoclonal antibody that binds CD47 on tumor cells and blocks its interaction with SIRPa on phagocytic cells. This relieves inhibition of macrophage activation and allows calreticulin-LRP-1 signaling that drives phagocytosis of tumor cells. It is studied in advanced tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
CD47, signal regulatory protein alpha (SIRPA) (binding partner it blocks), calreticulin (CALR) (binding partner it blocks)
Mechanism
Antagonist of CD47
Pathways
CD47/SIRPa signaling, macrophage activation, phagocytosis of tumor cells
Therapy area
Oncology
Developer
Hutchmed (HCM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05429008 Phase 1 Advanced Tumors Completed HCM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Tumors

Other drugs acting on CD47

More from Hutchmed

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the HCM page.

Follow HCM, the company behind HMPL-A83

See HCM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

HCM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.